Intra-Cellular Therapies Inc expected to post a loss of 92  cents a share - Earnings Preview

Intra-Cellular Therapies

06/05/2022 19:38

* Intra-Cellular Therapies Inc  ITCI.OQ   ITCI.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 10. 
    * The New York City-based  company is expected to report  a
111.9% increase in revenue to $33.652 million from $15.88
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Intra-Cellular
Therapies
Inc is for a loss of 92 cents per share. For the same quarter
last year, the company reported a loss of 65 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.4%
in the last three months. ​
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $70​, above​ its last closing price of $48.69.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.99       -0.99      -1.05     Missed  -5.6
 Sep. 30 2021  -0.92       -0.92      -0.95     Missed  -3.3
 Jun. 30 2021  -0.77       -0.79      -0.85     Missed  -7.4​
 Mar. 31 2021  -0.81       -0.80      -0.65     Beat    18.9
 ​​Dec.        -0.83       -0.85      -0.76     Beat    10.1
 31 2020                                                
 Sep. 30 2020  -0.99       -1.00      -0.79     Beat    20.7​
 Jun. 30 2020  -0.89       -0.91      -0.96     Missed  -5.6
 Mar. 31 2020  -0.91       -0.93      -0.73     Beat    21.2
 This summary was machine generated May 6 at 18:37 GMT.  All
figures in US dollars  unless otherwise stated